About CivaTech Oncology
CivaTech Oncology is a Healthcare company based in Durham (United States) founded in 2006. Polymer-based devices for low-dose brachytherapy in solid tumors are provided. CivaTech Oncology has raised $12.4 million across 18 funding rounds from investors including NIH, HHS and National Cancer Institute. CivaTech Oncology offers products and services including CivaSheet, CivaString, and CivaDerm. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is CivaTech Oncology Inc. Its competitors include Koya Medical, Sensus Healthcare and Theragenics; 3 of its 3 listed competitors have raised funding.
Company details
CivaTech Oncology was founded in 2006 in Durham, United States, and operates in the oncology sector. Polymer-based devices for localized low-dose-rate brachytherapy are developed and supplied to treat solid tumors. Key products include CivaString, a linear polymer-encapsulated source, and CivaSheet, an implantable membrane-like device, both used for targeted radiation delivery in clinical settings.
- Headquarters Durham, United States
- SectorsHealthcare
- Website civatechoncology.com
- Social LinkedIn X Facebook Instagram
- Legal Name Civatech Oncology Inc
- Total Equity Funding$12.4M (USD)
in 18 rounds
- Latest Funding Round$7.94M (USD), Series A
Nov 2021
- InvestorsNIH
& 2 more
Products & Services of CivaTech Oncology
CivaTech Oncology offers a comprehensive portfolio of products and services, including CivaSheet, CivaString, and CivaDerm.
Flexible, bioabsorbable source for planar radiation in cancer treatment.
Linear source for treating localized solid tumors effectively.
Temporary product for intraoperative skin cancer radiation therapy.
Funding Insights of CivaTech Oncology
CivaTech Oncology has successfully raised a total of $12.4M across 18 strategic funding rounds. The most recent funding activity was a Series A round of $7.94 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.4M
- Total Rounds 18
- Last Round Series A — $7.94M
- First Round $800,000
(Jun 2007)
- Investors Count 3
Latest 10 of 18 funding rounds of CivaTech Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $7.94M | Series A | – | – | – |
| Apr 2021 | $2.49M | Grant | – | – | |
| Dec 2017 | $15,000 | Debt – Conventional | – | – | – |
| Aug 2017 | $916,134 | Seed | – | – | – |
| Dec 2016 | $2.71M | Debt – Conventional | – | – | – |
| Sep 2016 | $5.32M | Grant | – | – | |
| Aug 2016 | Debt – Conventional | – | – | – | |
| Jul 2014 | $1.52M | Seed | – | – | – |
| Jun 2013 | $400,000 | Seed | – | – | – |
| Apr 2013 | $700,313 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in CivaTech Oncology
CivaTech Oncology has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States |
Investor details for CivaTech Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CivaTech Oncology
26 people are tracked at CivaTech Oncology (7 in leadership, 14 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Scott Mathis | Chairman & CEO | Leadership |
Sergio Manzur Odstrcil | CFO, COO, Algodon Wine Estates & Algodon Mansion | Leadership |
Maria Echevarria | Chief Financial Officer | Leadership |
Eric Stear | Ambassador, Director of Marketing | Leadership |
Randy Harrison | National Sales Director | Leadership |
Kristy Perez | Vice President Of Clinical Programs | Leadership |
David Reinecke | Director | Leadership |
Jasper A. van Duuren | Advisor | Board & advisors |
Nicholas Turner | Advisor | Board & advisors |
A. William Allen | Director | Board & advisors |
Marc Dumont | Director | Board & advisors |
Kye Hellmers | Advisor | Board & advisors |
Doug Casey | Advisor | Board & advisors |
Matteo Cecchetto | Advisor | Board & advisors |
Domenico Pecorini | Advisor | Board & advisors |
Reuben Cannon | Director | Board & advisors |
Stephen Falk | Advisor | Board & advisors |
Javier Medin | Advisor | Board & advisors |
Jack Laschever | Advisor | Board & advisors |
Jeroen P.a. Van Duuren | Advisor | Board & advisors |
6 more people are available in the full profile.
Complete people profiles for CivaTech Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CivaTech Oncology
3 dated milestones of CivaTech Oncology across 15 years, from founding to its latest funding, stage changes and deals.
- Founded CivaTech Oncology is founded.
- Funding First funding round of $800K.
- Funding Latest funding round, Series A, of $7.9M.
Competitors of CivaTech Oncology
CivaTech Oncology has 3 listed competitors in our database, 3 of them funded. They include Koya Medical, Sensus Healthcare and Theragenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| koyamedical.com | 2018 | Oakland, United States | $37.02M | 122 | Provider of smart wearable compression technology for lymphedema and venous diseases | |
| sensushealthcare.com | 2010 | Boca Raton, United States | $12.24M | 42 | Non-invasive skin cancer treatments are developed and marketed. | |
| theragenics.com | 1981 | Buford, United States | $9.44M | 566 | Manufacturer of surgical products and brachytherapy devices |
Detailed competitors of CivaTech Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CivaTech Oncology
The website of CivaTech Oncology (civatechoncology.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 1.5% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as CivaTech Oncology (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Civatech Oncology
Complete news archive for CivaTech Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CivaTech Oncology
CivaTech Oncology was founded in 2006 and raised its 1st funding round 1 year after it was founded.
CivaTech Oncology is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
CivaTech Oncology is a funded company, having raised a total of $12.4M across 18 funding rounds to date. The company's 1st funding round was a Seed of $700.31K, raised on Jun 2007.
CivaTech Oncology was founded in 2006 in Durham, United States, and operates in the oncology sector. Polymer-based devices for localized low-dose-rate brachytherapy are developed and supplied to treat solid tumors. Key products include CivaString, a linear polymer-encapsulated source, and CivaSheet, an implantable membrane-like device, both used for targeted radiation delivery in clinical settings.
CivaTech Oncology's top competitors include Koya Medical, Sensus Healthcare and Theragenics.
CivaTech Oncology offers CivaSheet, CivaString, and CivaDerm.
CivaTech Oncology has 3 investors. Key investors include NIH, HHS, and National Cancer Institute.
CivaTech Oncology operates through Civatech Oncology Inc.